SMMTSummit Therapeutics Inc.

Sign up free
⚡

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 - Yahoo Finance

Yahoo Finance · Nov 4, 9:36 PM

Market reactionShares rose 15% on Nov 6.

ChallengedLast material event Nov 4, 2026

Biliary cancer survival results strengthen expansion potential; lung cancer FDA decision remains central

Summit Therapeutics is a clinical-stage company developing ivonescimab, a cancer drug under FDA review for EGFR-mutant lung cancer after targeted therapy; partner Akeso sells it in China.

Summit's case depends on ivonescimab's FDA decision after EGFR-targeted therapy, global first-line HARMONi-3 results, and funding through launch. HARMONi met progression-free survival significance but missed primary overall-survival significance; later follow-up was favorable. AstraZeneca's investment supports development. China-only HARMONi-GI1 now quantifies survival superiority over durvalumab plus chemotherapy, strengthening expansion beyond lung cancer. Planned Datroway trials, the opened kidney cancer study, and endometrial cancer responses broaden opportunities and spending demands.

Thesis checklist

0 risks need attention

Select a row for evidence
FDA approves ivonescimab after EGFR-targeted therapyAwaiting evidenceNext: FDA's decision and the population covered by any approved label.

Why it is in this state

The evidence, what would weaken it and the source filing

HARMONi-3 extends benefit to first-line lung cancerAwaiting evidenceNext: HARMONi-3 progression-free survival results, with each histology assessed separately.

Why it is in this state

The evidence, what would weaken it and the source filing

Survival benefit over Keytruda holds upSupportedNext: Global comparative results, distinguishing HARMONi-3 chemotherapy combinations from HARMONi-2 monotherapy.

Why it is in this state

The evidence, what would weaken it and the source filing

Funding covers launch and the Phase 3 programSupportedNext: Updated cash, spending, and conditional runway guidance incorporating launch preparation and expanded trial commitments.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

FDA decision on ivonescimab after EGFR-targeted therapy

Tests: FDA approves ivonescimab after EGFR-targeted therapy

November 14, 2026 PDUFA goal date

Does FDA approve ivonescimab plus chemotherapy for EGFR-mutant lung cancer after a third-generation EGFR inhibitor?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentClinical
-6.3%Nov 4, 2026

Biliary cancer survival results strengthen expansion potential; lung cancer FDA decision remains central

ChallengedClinical
-1.8%Oct 22, 2026

Endometrial cancer responses broaden potential; lung cancer FDA decision remains central

ChallengedCorporate
+5.9%Sep 28, 2026

FDA decision remains next as biliary tract cancer development expands

ChallengedRegulatory
-5.5%Sep 15, 2026

Ivonescimab beat Keytruda on OS; November BLA decision and going-concern clock test US approval before balance sheet breaks

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Non-small cell lung cancer· EGFRm+ · second-line or later
ivonescimab · 1 upcoming
PDUFA Decision
Nov 14, 2026
Non-small cell lung cancer· first-line · squamous
ivonescimab · 1 upcoming · 1 completed
Phase 3 DataHARMONi-3
Q4 2026
Non-small cell lung cancer· first-line · non-squamous
ivonescimab · 1 upcoming
Phase 3 DataHARMONi-3
H1 2027
Non-small cell lung cancer· first-line · PD-L1 high
ivonescimab · 1 upcoming · 1 completed
Phase 3 Enrollment: CompletionHARMONi-7
2027
Head and neck squamous cell carcinoma· recurrent/metastatic · PD-L1 positive
ivonescimab · 1 upcoming
ILLUMINE Phase III in r/m HNSCC (GORTEC-sponsored)
TBD
Gastrointestinal cancers
ivonescimab · 1 upcoming
Study Initiation
TBD
Multiple cancer types
ivonescimab · 1 upcoming
Study Initiation
TBD
Triple negative breast cancer· first-line
ivonescimab · 1 upcoming
Phase 3 Study Initiation
TBD
Clear cell renal cell carcinoma· first-line · advanced
ivonescimab · 1 upcoming
Phase 2 DataSMT112-216
TBD
Multiple solid tumors
ivonescimab · 1 upcoming
Study Initiation
TBD
Colorectal cancer· first-line · unresectable metastatic
ivonescimab · 1 upcoming
Phase 3 Study InitiationGI3
ongoing
Non-small cell lung cancer· first-line
ivonescimab · 1 completed
Phase 3 Enrollment: CompletionHARMONi-3
Reported Nov 4, 2026
Biliary tract cancer· first-line · advanced
ivonescimab · 1 completed
Phase 3 Data: InterimHARMONi-GI1China
Reported Sep 15, 2026
Non-small cell lung cancer· PD-L1 positive · advanced
ivonescimab · 1 completed
Phase 3 Data: FinalHARMONi-2
Reported Sep 15, 2026
EGFR-mutated NSCLC· post-EGFR TKI
ivonescimab · 1 completed
BLA SubmissionPivotal
Reported Nov 7, 2025
Non-small cell lung cancer· post-EGFR-mutated · post-TKI
ivonescimab · 1 completed
Phase 3 Data: ToplineHARMONiPivotal
Reported May 30, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Summit Therapeutics (SMMT) investment thesis intact?
It is under pressure. Readouts currently rates the Summit Therapeutics Thesis Challenged. Biliary cancer survival results strengthen expansion potential; lung cancer FDA decision remains central.
What is the next catalyst for Summit Therapeutics (SMMT)?
The next dated event is the FDA decision on Ivonescimab, on Nov 14, 2026, as stated by the company. Also ahead: Phase 3 results (HARMONi-3) for Ivonescimab, expected Q4 2026.
How long will Summit Therapeutics' cash last?
Summit Therapeutics has said its cash will fund operations beyond Nov 2027 (guidance as of November 4, 2026).

Other companies we cover in these diseases

Clear cell renal cell carcinoma
Arcus Biosciences (RCUS)
Head and neck squamous cell carcinoma
Corbus Pharmaceuticals (CRBP)Pyxis Oncology (PYXS)
Non-small cell lung cancer
Immutep (IMMP)

Drug pages: Ivonescimab
Disease areas: Lung cancer, Breast and gynecologic cancers, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

7 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.